The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
AKERO THERAPEUTICS INC COM 00973Y108 89,973 3,954,858 SH   SOLE   3,954,858 0 0
APELLIS PHARMACEUTICALS INC COM 03753U106 24,090 1,000,000 SH   SOLE   1,000,000 0 0
MENLO THERAPEUTICS INC COM 586858102 6,548 1,461,552 SH   SOLE   1,461,552 0 0
PRECISION BIOSCIENCES INC COM 74019P108 35,785 4,265,141 SH   SOLE   4,265,141 0 0
TURNING POINT THERAPEUTICS I COM 90041T108 50,394 1,340,265 SH   SOLE   1,340,265 0 0
VERONA PHARMA PLC SPONSORED ADS 925050106 3,999 875,000 SH   SOLE   875,000 0 0